
For research use only. We do not supply to patients.
For pharmaceutical-grade products or other inquiries, please contact our experts.
An amphipathic polyglutamic acid (PGA)-based formulation of amphotericin B (AmB) was prepared by self-assembly. AmB-loaded PGA nanoparticles (98±2 nm; zeta potential: -35.2±7.3 mV) displayed high stability in PBS and serum (<20% release after 10 days), lower hemolytic toxicity (≤15% lysis at 100 µg/mL) and preserved antifungal potency compared to Fungizone. Cell viability of mammalian cells determined by MTT assay showed no cytotoxicity at 200 µg/mL and no kidney necrosis was observed by histopathology. The formulation also demonstrated potent activity against C. albicans and inhibited biofilm formation comparable to Fungizone. These PGA nanoparticles encapsulating AmB show promise to retain antifungal activity while minimizing toxicity.
Fig. 2 Scanning electron micrographs of inhibition of Candida albicans biofilm mediated by the AmB–PGA formulation. (Urimi D, et al. 2019)
References
Cat NO.: CIA823202999-2
CAS NO.: 823202-99-9
Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed
All our products are chemicals for research purposes only. We do not supply for human or veterinary applications.
Privacy Policy | Cookie Policy Copyright © Protheragen. All Rights Reserved.
